Henning Walczak

Founder at Apogenix AG

Health Technology

Health Services

Profile

Henning Walczak is the founder of Apogenix AG, which was founded in 2005.
He also worked as the Head-BioFuture Research Group at the German Cancer Research Center.

Henning Walczak active positions

Companies	Position	Start
Apogenix AG Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany.	Founder	24/11/2009

All active positions of Henning Walczak

Former positions of Henning Walczak

Companies	Position	End
German Cancer Research Center German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany.	Corporate Officer/Principal	-

See the detail of Henning Walczak's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Henning Walczak's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Apogenix AG Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany.	Health Technology
German Cancer Research Center German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany.	Health Services